All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-CD19 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human CD19. The T cells are genetically modified through transduction with a retroviral vector expressing inducible Casp9, IL-15 and scFv of anti-CD19 antibody linked to CD3-zeta and CD28 signaling domains. An iCasp9 allows for the removal of inappropriately activated CAR T cells. And the vector product was designed for the treatment of chronic lymphoid leukemia.
CAR Construction : Fig.1 Relative binding affinities of clone Denintuzumab/huB4 and huB4-DGN462 on Ramous cells. Hicks, S. W., Tarantelli, C., Wilhem, A., Gaudio, E., Li, M., Arribas, A. J., ... & Bertoni, F. (2019). The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models. haematologica, 104(8), 1633. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-CD19 (Denintuzumab) h(CD28-CD3ζ,iCasp-9, IL-15) Self-destruct CAR, pCDCAR1 (CAR-LC381). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION